Premium
New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease
Author(s) -
Shelton E.,
Chaudrey K.,
Sauk J.,
Khalili H.,
Masia R.,
Nguyen D. D.,
Yajnik V.,
Ananthakrishnan A. N.
Publication year - 2015
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13159
Subject(s) - medicine , infliximab , adalimumab , gastroenterology , alanine transaminase , transaminase , inflammatory bowel disease , aspartate transaminase , tumor necrosis factor alpha , disease , enzyme , biochemistry , chemistry , alkaline phosphatase
Summary Background Anti‐tumour necrosis factor α (anti‐ TNF ) agents have been implicated in drug‐induced liver injury. There is minimal data on this occurrence in inflammatory bowel disease ( IBD ) patients. Aim To identify the characteristics of liver enzyme elevations following anti‐ TNF therapy initiation in IBD . Methods A retrospective cohort of patients initiating anti‐ TNF therapy were analysed for new onset alanine transaminase ( ALT ) elevation (≥60 U/L). We collected data on natural history, outcomes and patient characteristics compared with controls with persistent normal liver enzymes. Likelihood of causal association was assessed using the RUCAM score. Results From 1753 patients initiating an anti‐ TNF (1170 infliximab, 575 adalimumab, 8 certolizumab), 102 (6%) developed new onset ALT elevation. In 54 (53%), this could be linked to an alternate aetiology. Among those with idiopathic ALT elevations, the median time to ALT elevation from anti‐ TNF initiation was 18 weeks and median peak ALT was 96 U/L. Six underwent liver biopsy, all demonstrating hepatitis with autoimmune features. Compared to controls, cases were on a lower dose of infliximab (5.7 vs. 6.7 mg/kg, P = 0.02) but were otherwise similar in body mass index, sex and age. On follow‐up, 34 continued the anti‐ TNF , 14 stopped therapy and 4 initiated steroids. Most (85%) normalised their LFT s after a median of 17 weeks including 28 (82%) of those who continued anti‐ TNF therapy. Ten patients were transitioned to a second anti‐ TNF without recurrence. Conclusions ALT elevations occurred in 6% of IBD patients initiating anti‐ TNF therapy. Most idiopathic elevations were mild, transient and resolved despite therapy continuation.